Please login to the form below

Not currently logged in
Email:
Password:

Versartis names chief financial officer

Joshua Brumm joins from Pharmacyclics

Versartis has named Joshua Brumm as its first chief financial officer.

Brumm joins from Pharmacyclics where he was principal financial officer and executive VP of finance.

He already has life sciences financial experience, having previously served as chief financial officer for Zeltiq Aesthetics and director of finance at Proteolix.

In his new role at Versartis, Brumm will lead the company's financial operations as it prepares to for the commercialisation of its phase III prospect VRS-317, which is in development as a treatment for growth hormone deficiency.

The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will significantly strengthen our management team."

18th December 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics